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Purpose—NRG Oncology RTOG 1014 is a prospective phase II trial of 3D-CRT PBrI following
repeat lumpectomy for in-breast recurrence following previous whole breast irradiation (WBI).
The primary goal of the trial was to determine the associated toxicity, tolerance and safety of PBrI.
Materials and Methods—Eligibility criteria included in-breast recurrence occurring >1 year
following WBI, <3cm, unifocal and resected with negative margins. PBrI was targeted to surgical
cavity + 1.5 cm; prescription dose of 45 Gy in 1.5Gy BID for 30 treatments was used. The primary
objective was to evaluate the rate of grade ≥3 treatment-related skin, fibrosis, and/or breast pain
adverse events (AEs), occurring ≤1 year from re-treatment completion. A rate of ≥13% for these
AEs in a cohort of 55 patients was determined to be unacceptable, 86% power, 1-sided α=0.07.

Author Manuscript

Results—Between 2010 and 2013, 65 patients were accrued and the first 55 eligible and with 1
year follow-up were analyzed. Median age is 68 years. 22 patients had DCIS and 33 invasive
disease; 19 ≤1cm, 13 >1 to ≤2cm and 1 >2cm. All patients were clinically node-negative.
Systemic therapy was delivered in 51%. All treatment plans underwent quality review for
contouring accuracy and dosimetric compliance. All treatment plans scored acceptable for tumor
volume (TV) contouring and TV dose volume analysis (DVA). Only 4 (7%) scored unacceptable
for organs at risk (OAR) contouring and OAR DVA. Treatment-related skin, fibrosis, and/or breast
pain AEs were recorded as grade 1 in 64%, grade 2 in 7% with only 1 (<2%) grade ≥3 and
identified as grade 3 fibrosis of deep connective tissue.
Conclusion—PBrI with 3D-CRT following second lumpectomy for patients experiencing inbreast failures after WBI is safe and feasible with acceptable treatment quality achieved. Skin,
fibrosis and breast pain toxicity was acceptable and grade 3 toxicity was rare.

Author Manuscript
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Introduction
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Breast conservation surgery (BCS) followed by whole breast irradiation (WBI) yields
excellent in-breast control rates and is recognized as a standard of care option for local
treatment of properly selected patients. Long term follow-up of patients treated with BCS
and WBI finds that in-breast failure rates are approximately 10%.1 Mastectomy is the
acknowledged treatment of choice when encountering an in-breast failure following WBI.
This has become accepted for reasons including the perception that mastectomy is the only
logical next step, concerns over cosmetic outcomes following additional surgery and
complication rates following additional radiotherapy. Published outcomes suggest that a
mastectomy may not be the definitive answer, as chest wall failure rates following a
mastectomy for in-breast failure after WBI range from 3–32%.2–15 (Table 1) It is recognized
that these are older series with variable follow up and that the stage at presentation, in-breast
recurrence extent and surgical details are not available to allow modern perspective
regarding anticipated chest wall recurrence rates. However, this suggests that exploration of
alternative options is appropriate. Attempts at continued breast conservation are represented
through the limited series of repeat BCS alone that have been reported with poor in-breast
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control rates.9,11,12,15,16 (Table 2) The lack of reported surgical margin status and
description of imaging use make it difficult to extrapolate these results into present-day
practice. Nevertheless, the rate of second in-breast failure is significant and consistent with
results following lumpectomy only for primary disease. Whole breast irradiation in this
setting is discouraged given the potential for serious late toxicity related re-irradiation of
sensitive normal tissue such as lung and heart. The acceptance of partial breast irradiation as
an alternative to whole breast irradiation in the setting of de novo breast conservation makes
it a logical solution to apply to repeat breast conserving surgery in an attempt to reduce the
2nd in-breast recurrence rates to acceptable levels while avoiding excessive toxicity. Early
and limited investigation of this approach has generated outcome data that suggests this may
be an appropriate direction to pursue if continued breast conservation is preferred.17–23
(Tables 1 and 2).

Author Manuscript

Therefore, it is proposed that in properly selected patients facing an in-breast failure after
initial lumpectomy and WBI, repeat BCS followed by partial breast re-irradiation (PBrI)
could yield acceptable results. This manuscript is the first report from the NRG Oncology
RTOG 1014 prospective phase II trial of 3D-conformal external beam (3D-CRT) PBrI
following repeat lumpectomy for in-breast recurrence following previous WBI. The primary
endpoint is to evaluate skin, breast, and chest wall adverse events (AEs) occurring within 1
year from the completion of re-irradiation and is the focus of this report. Additional
endpoints of local recurrence, cosmesis, and circulating tumor cells require additional
follow-up and will be reported in the future.

Materials and Methods
Eligibility Criteria

Author Manuscript
Author Manuscript

Protocol approval was received from the Institutional Review Board at each study site and
informed consent was obtained from each patient prior to participation. Patient eligibility
criteria were defined to select patients with low likelihood of extensive in-breast recurrence
with the risk of microscopic disease confined to the immediate vicinity of the lumpectomy
cavity. In-breast failures could represent either delayed failure of the original tumor or a new
primary within the same breast. Eligibility criteria included unicentric breast lesions by MRI
that were ≤ 3 cm and without evidence of skin involvement, which occurred one year or
more following initial breast conserving therapy. Histologically, recurrent tumors were to be
consistent with invasive ductal, medullary, tubular, mucinous, lobular or ductal carcinoma in
situ. Documentation of a negative metastatic work-up was required for invasive recurrences
by either whole body Positron Emission Tomography - Computed Tomography (PET/CT) or
a combined CT of the chest, abdomen, pelvis and bone scan. Being ≥ 18 years old and
having breast conserving surgery with anticipated acceptable cosmesis and obtaining
negative histologic margins of resection, no tumor on ink (re-excision was permitted to
achieve negative margins) were requisites. Based on a postoperative, pretreatment CT scan
the target lumpectomy cavity needed to be clearly defined and the target lumpectomy cavity/
whole breast reference volume <30% for study entry.
Axillary management was dependent on the in-breast recurrence histology and previous
axillary surgery. Patients with 0–3 positive axillary lymph nodes without extracapsular
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.
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extension were eligible for enrollment. Axillary evaluation beyond a node negative clinical
exam consisted of ultrasound, sentinel node evaluation and/or axillary node dissection
(ALND) depending on histology and previous axillary surgery. Any suspicious areas were to
be biopsied and if positive, followed with an ALND. Any patients presenting with a positive
axillary clinical exam were required to undergo biopsy and if positive, follow with an
ALND.
Target definition and dose delivery

Author Manuscript

Supine or prone treatment positioning was allowed and a treatment planning CT scan with
required target volumes and organs at risk outlined on all CT slices was required. This
included the clinical target volume (CTV), planning target volume (PTV) and PTV for
Evaluation (PTV_EVAL), skin, ipsilateral and contralateral whole breast reference volume,
thyroid, ipsilateral and contralateral lung, and heart (see Supplemental Appendix). The
excision cavity was outlined based either on clear visualization on CT or, if placed, with the
help of surgical clips. The CTV was defined by uniformly expanding the excision cavity
volume by 15 mm with limitation to 5 mm from the skin surface and the posterior breast
tissue extent (chest wall structures and pectoralis muscles were not included). The PTV
provided a margin around the CTV to compensate for the variability of treatment setup and
motion of the breast with breathing. The PTV was defined as a minimum of 10 mm around
the CTV. The PTV_EVAL was generated and used for dose volume histogram analysis
(DVA) constraints. The PTV_EVAL was defined as the PTV bounded and limited to exclude
the first 5 mm of tissue under the skin and excludes any the PTV expansion beyond the
posterior extent of breast tissue.

Author Manuscript

Dose delivery specifications included the use of 3D-CRT PBrI to begin within 9 weeks after
last breast surgery. A total of 45 Gy was delivered in two fractions per day, each of 1.5 Gy,
separated by at least six hours and given in fifteen consecutive working days for a total of 30
fractions and 45 Gy.
Field arrangements were at the discretion of the physician and determined through 3Dtreatment planning to produce the optimal conformal plan in accordance with volume
definitions. The treatment plan used for each patient was based on analysis of the volumetric
dose including DVA of the PTV_EVAL and critical normal tissues. Dose calculations with
tissue inhomogeneity correction were used. Photon field combinations (with or without
electrons), and field within a field treatment approaches were accepted.
Quality assurance and rapid review

Author Manuscript

All cases were electronically submitted to the Image-Guided Therapy Quality Assurance
Center (ITC) for review with final evaluation by one of the radiation oncology protocol
investigators and judged as 1-per protocol, 2-variation acceptable or 3-deviation
unacceptable. Quality assurance (QA) rapid reviews were to be done on the first case from
each site before the start of treatment, unless previously participating on RTOG partial breast
irradiation (PBI) protocols. The subsequent cases submitted to ITC were reviewed in a
timely fashion with feedback of protocol guideline compliance to the participating
institution as needed. QA reviews for all cases were completed prior to this report.
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Treatment related toxicity is documented with use of the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0 of the National Cancer Institute. Protocol stipulates
evaluation and recording of any AEs occurring during radiation therapy, at 6 weeks from the
start of treatment and then at regular intervals to follow (every 3 months for 1 year, every 4
months for 2 years, every 6 months for 2 years and then annually).
Statistics

Author Manuscript

The primary objective of this study was to evaluate the rate (p) of grade ≥ 3 treatmentrelated skin, fibrosis, and breast pain AEs, as graded by CTCAE version 4.0, occurring
within 1 year from the completion of re-irradiation. Based on a rate of 4% for these AEs
from first line PBrI treatment in RTOG 0319, the investigators determined that a rate of 13%
or more for these AEs with re-irradiation would be unacceptable (H0: p ≤ 13% vs H1: p
>13%). A sample size of 55 evaluable patients (eligible and started protocol treatment)
provided the following: 86% power to conclude that the treatment has an unacceptable rate
of the specified AEs, if the true AE rate is at least 13%, and 93% probability to not conclude
that the treatment has an unacceptable rate of the specified AEs, if the true AE rate is ≤ 4%.
Adjusting this figure by 10% to allow for patients determined to be ineligible, that did not
start protocol treatment, or lack data, a total sample size of 61 patients was required for this
study.
If 5 or more, out of 55 evaluable patients, experience the treatment-related AEs specified
above, then that rate would be considered unacceptable and the treatment not be considered
further; otherwise the treatment-related AE rate would be acceptable and the treatment
considered for further study.

Author Manuscript

Results
This NRG Oncology RTOG 1014 was opened in June 2010 and completed accrual in June
2013. In this 3 year time period, 34 RTOG members and affiliates/satellites participated,
enrolling a total of 65 patients. Of those enrolled patients, 58 were determined to be
ultimately eligible and received protocol treatment. As per protocol, this analysis is confined
to the first 55 eligible patients who completed treatment and achieved 1 year of follow-up.

Author Manuscript

The overall compilation of pre-treatment patient and tumor characteristics are represented in
Table 3. The median age is 68 years old (min-max: 44–86). The majority of cases consisted
of invasive histology, 60% (n=33), with 40% (n=22) represented by ductal carcinoma in situ
(DCIS). The invasive tumors were small (n=19 ≤1cm, n=13 >1 to ≤2cm, and n=1 >2cm) and
the majority low to intermediate grade (69%) with only 31% high grade lesions. All tumors
were tested for estrogen and progesterone receptors and 76.4% were estrogen positive and
56% progesterone positive. Her2 testing was not available for 11 patients, but in those tested
8 (18%) were positive with 36 (82%) negative. All patients were clinically node negative
with 25% pathologically confirmed node negative. See Table 4 for axillary assessment
details. The mean time between treatment for the initial breast disease and the in-breast
failure was 14.9 years (median=14.0 years, min-max: 1.6–27.7). Systemic therapy was
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delivered in 51% of patients, with systemic chemotherapy alone in 6 (10.9%) patients,
hormone therapy alone in 21 (38.2%) patients, and both systemic chemotherapy and
hormonal therapy in 1 (1.8%) patient.

Author Manuscript

Summary dose information is shown in Supplemental Table 1. Median PTV_EVAL volume
is 242cc (min-max: 33.8–951.2cc), median ipsilateral breast volume is 1064cc (min-max:
102.5–3103.4cc), and the median PTV_Eval volume/ipsilateral breast volume is 22% (minmax: 7.7–49.3%). Overall contouring and dosimetric compliance was judged as
exceptionally good with rare unacceptable variations. Details of dose constraint criteria and
the ability to meet these constraints are shown in Table 5. Tumor volume contours were
scored as per protocol in 52 (94.5%) cases, 3 (5.5%) cases were scored as acceptable
variations and there were no unacceptable scores. Organs at risk (OAR) contours were
scored as per protocol in 38 (69.1%) cases, 13 (23.6%) as acceptable variations, and only 4
(7.3%) cases scored as unacceptable variations. High quality of treatment planning was
confirmed through the dose volume analysis (DVA) score of tumor volume analysis and
OAR. Tumor volume DVA were scored as per protocol in 54 (98.2%) cases, 1 (1.8%) as
acceptable variation, and there were no unacceptable scores. OAR DVA were scored as per
protocol in 45 (81.8%) cases, 5 (9.1%) as acceptable variations, and 5 (9.1%) cases as
unacceptable variations. In review of the cases with unacceptable variation scores, 5 cases
total were identified, 4 scoring unacceptable variation on both OAR contouring and OAR
DVA and 1 scoring acceptable variation on OAR contouring and unacceptable variation on
OAR DVA.

Author Manuscript

Treatment-related skin, fibrosis, and/or breast pain AEs are the primary endpoint for this
phase II protocol. In the first 55 patients evaluable, these specific AEs were recorded as
grade 1 in 64%, grade 2 in 7% with only 1 (<2%) grade 3. There were no grade 4 or 5 AEs
reported. The skin and subcutaneous tissues disorders represented the majority of the
reported grade 1 and grade 2 events. The documented grade 3 AE was represented by
fibrosis of deep connective tissue (Table 6). Since there were fewer than 5 grade ≥ 3
treatment-related skin, fibrosis, and breast pain AEs, the treatment-related AE rate is
considered to be acceptable.

Discussion

Author Manuscript

This trial demonstrates acceptable toxicity and safety of a second breast conservation using
lumpectomy and partial breast re-irradiation for management of in-breast recurrence
following initial breast conservation where whole breast irradiation was delivered. Several
publications have previously reported small experiences that describe early outcome results
following repeat breast conservation and partial breast re-irradiation.18–23 Each experience
has contributed to the overall understanding of this approach and helped to support the
initiation of NRG Oncology RTOG 1014. One of the first experiences reported is from
France where investigators offered repeat breast conservation treatment only to women that
either refused mastectomy or when mastectomy was contraindicated.21 Treatment of the inbreast failure consisted of re-resection followed by partial breast brachytherapy using 30Gy
total dose delivered with low dose rate multicatheter brachytherapy (MCB). The study
included 15 patients with a mean tumor size of 2.4 cm. Following this focused treatment, a
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second in-breast recurrence was encountered in 26% (n=4 patients) at a mean follow-up of
48 months. Major sequelae were reported in 3 patients. Of these 3, one patient with skin
necrosis was treated with local wound care and one patient had a mastectomy performed.
Resch, et al, followed years later in 2002 with an additional small study. In this experience,
17 patients were treated after encountering an in-breast failure following breast conserving
therapy that included WBI.22 Nine patients followed local resection with 40–50 Gy partial
breast treatment delivered with multicatheter technique. The remaining eight patients
received repeat WBI to 30Gy followed by 12.5Gy delivered to a partial breast target with
MCB. There were four second recurrences reported with a mean follow up of 50 months.
Interestingly, all were within the group treated with repeat WBI and MCB. Toxicity was
acceptable with only grade 1–2 fibrosis encountered.

Author Manuscript

Deutsch, et al., from the University of Pittsburgh Medical Center, published a study of repeat
irradiation for in-breast tumor recurrence after prior lumpectomy and whole breast
irradiation using external beam radiotherapy after re-resection.23 Thirty-nine patients were
treated in this study, 31 invasive and 8 non-invasive diseases. All patients underwent
resection of the recurrence to achieve negative pathologic margins with 15% of cases
reported to ultimately have resection margins that were positive. Following local resection,
external beam re-irradiation to the operative bed with 50 Gy in 25 fractions was delivered.
At a median follow-up of 52 months, a second local in-breast recurrence was encountered in
20.5% of patients. Contralateral breast cancer occurrence in this cohort study was also
20.5%. There were no reports of radiation-induced necrosis.

Author Manuscript

Chadha, et al, published an additional experience from Beth Israel Medical Center in New
York City, NY.20 This phase I/II study evaluated the role of partial breast MCB following
local resection of a local recurrence/new primary following standard WBI. Fifteen patients
were treated post lumpectomy with low dose rate brachytherapy utilizing a total of 30Gy for
the first six patients and 45Gy for the subsequent nine patients. Median follow-up was 36
months. They reported only one re-recurrence, and therefore, an overall in-breast control rate
of 89%. No grade 3 or 4 toxicities reported.
In an additional small study published by Trombetta, et al., balloon based brachytherapy was
used to deliver PBrI after local resection for in-breast failure following BCS and WBI.19
Eighteen patients were included in this study and reported with a mean follow up of 39.6
months. Results were again encouraging with only 2 patients recorded as having an in-breast
re-recurrence and 2 patients with infection of which one required a mastectomy.

Author Manuscript

The largest study that has been published on this subject is the multicenter GEC-ESTRO
European trial (The Groupe Européen de Curiethérapie (GEC) and the European Society for
Radiotherapy & Oncology (ESTRO).18 This experience of 217 patients was reported in 2013
with a mean follow up of 3.9 years. All patients had previously been treated with BCS and
WBI and documented to have an in-breast failure. Repeat treatment on this trial consisted of
local resection of the recurrent disease and MCB. They reported a 5-year actuarial rerecurrence rate of only 5.6% with limited grade 3–4 complications (11%).
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The published literature corroborates the hypothesis of this trial that local resection followed
by partial breast re-irradiation could be an appropriate alternative treatment approach to
mastectomy for the local management of an in-breast failure following BCS and WBI. The
growing experience in the use of 3D-CRT PBI and that it is widely available, reproducible,
and could reliably deliver a homogeneous dose to previously irradiated tissue confirmed that
this method needed to be studied in this setting. Furthermore, the established treatment
guidance with existing outcome data from the previously successful RTOG 0319 phase II
protocol provided a platform from which to build.24,25 To further reduce the risk of grade 3
tissue toxicity, a hyperfractionated dose regimen was decided upon. This provided the
opportunity to use a dose fractionation scheme modeled after the head and neck re-treatment
experience − 1.5 Gy bid X 30 treatments and a total of 45 Gy.26–28 The intent was to assure
the highest level of disease control and low risk of toxicity with optimal cosmetic outcome.
Therefore, dose homogeneity and the dose fractionation scheme were believed to be
optimized.

Conclusion

Author Manuscript

Initial AE data from NRG Oncology RTOG 1014 investigating PBrI with 3D-CRT following
second lumpectomy for patients experiencing in-breast failures after lumpectomy and WBI
suggests promising outcome and supports continued investigation. Despite previous whole
breast irradiation, PBrI delivered with 3D-CRT is well tolerated and at the 1-year follow-up
interval is found to be safe and feasible with acceptable treatment quality achieved. In the
RTOG 0319 phase II protocol, 3D-CRT was used in an accelerated fashion (3.85Gy bid X 10
delivered in 5 days) for primary breast conserving therapy for early stage breast cancer and
reported a grade 3 toxicity event rate of 4%. In this trial of PBrI in patients with in-breast
failure after WBI, a protracted hyperfractionated course of treatment was utilized. The
fractionation scheme applied in this protocol was based on previous re-treatment
experiences, however, it is recognized that alternative fractionation schemes may be
appropriate. Grade 1 skin, fibrosis and breast pain was documented in a large number of
patients as expected, however, grade 2 toxicity was infrequent at 7% and grade 3 toxicity
was rare at <2%. This initial report suggests that the primary hypothesis, local resection
followed by PBrI for an in-breast failure following WBI is safe and feasible, is correct.
Further follow up is necessary for confirmation of long-term safety and to address the ability
to achieve in-breast disease control with an acceptable long term cosmetic outcome and the
ability to avoid mastectomy.
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Refer to Web version on PubMed Central for supplementary material.
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Summary
NRG Oncology RTOG 1014 is a phase II trial investigating partial breast re-irradiation
(PBrI) with 3D-CRT following second lumpectomy for patients experiencing in-breast
failures after whole breast irradiation (WBI). At the 1 year follow up interval, PBrI
delivered with 3D-CRT technique is found to be well tolerated, safe and feasible with
acceptable treatment quality achieved.
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Table 1

Author Manuscript

Chest wall failure rates following mastectomy for in-breast failure following lumpectomy and WBI

Author Manuscript

No. of pts

Med. F/U (mo’s)

Chest wall re-recurrence rate (%)

5-yr OS rates (%)

Clarke, et al, 1985

12

26

27

-

Recht, et al, 1989

65

32

9

-

Kurtz, et al, 1989

43

53

12a

53

Forquet, et al, 1989

39

63

-

73

Fowble, et al, 1990

52

25

-

84

****

41

60

-

59

Osborne, et al, 1992

46

28

31

76

Abner, et al, 1993

106

39

7

79

Cajucom, et al, 1993

25

52

32

65

Dalberg, et al, 1998

65

156

19

-

Salvadori, et al, 1999

134

73

4

70

Doyle, et al, 2001

112

44

3

83

Huang, et al, 2002

118

84

20

52b

Abbreviations: No., number; Med., median; F/U, follow-up; mo’s, months; yr, year; OS, overall survival

a
chest wall and regional failures
b

true recurrences
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Table 2

Author Manuscript

In-breast re-recurrence rates following repeat lumpectomy only for in-breast failure following lumpectomy
and WBI
No. of pts

Med. f/u (mo’s)

In-breast re-recurrence rate (%)

5-yr OS (%)

Kurtz, et al, 1991

55

51

27

-

Abner, et al, 1993

16

39

31

81

Dalberg, et al, 1998

14

156

50

-

Voogd, et al, 1999

16

52

38

-

Salvador, et al, 1999

57

73

19

85

Abbreviations: No., number; Med., median; F/U, follow-up; mo’s, months; yr, year; OS, overall survival
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Table 3

Author Manuscript

First 55 Evaluable Patients: Patient and Tumor Characteristics
Patient or Tumor Characteristic

n

%

Age (years)
Median

68

Min - Max

44 – 86

Q1 – Q3

59 – 73

Race
Asian

1

1.8

Black or African American

8

14.5

White

45

81.8

Unknown

1

1.8

0

52

94.5

1

3

5.5

DCIS

22

40.0

Invasive Histologies

33

60.0

≤ 0.5 cm

6

18.2

>0.5 to ≤ 1.0 cm

13

39.4

>1.0 to ≤ 2.0 cm

13

39.4

>2.0 cm

1

3.0

Low grade

8

14.5

Intermediate grade

30

54.5

High grade

17

30.9

Stage 0

21

38.2

Stage I

33

60.0

Stage IIA

1

1.8

Positive

42

76.4

Negative

13

23.6

Positive

31

56.4

Negative

24

43.6

11

20.0

Positive

8

14.5

Negative

36

65.5

Zubrod Performance Status

Author Manuscript

Histology

Size - largest dimension

Histology Grade

Author Manuscript

Stage (AJCC

7th

Edition)

Estrogen Receptor Status

Progesterone Receptor Status

Author Manuscript

Her2 Status
Not applicable/Not done

Q1 = first quartile; Q3 = third quartile

Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.

Arthur et al.

Page 15

Table 4

Author Manuscript

First 55 Evaluable Patients: Information on Sentinel Lymph Nodes and Axillary Nodes (n=55)
Node Information

n

Invasive Lesions

%

(n=33)

No SLNB/No ALND

13

39.4

SLN not identified/No ALND

8

24.2

Yes SLNB/No ALND

9*

27.3

Yes SLNB/Yes ALND

3*

9.1

DCIS

(n=22)

Author Manuscript

No SLNB/No ALND

18

81.8

No SLNB/Yes ALND

1*

4.6

SLN not identified/No ALND

2

9.1

Yes SLNB/Yes ALND

1*

4.6

Abbreviations: SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection

*

All node negative
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Thyroid (n=1, missing)

Heart (n=1, missing)

Contralateral Lung

Ipsilateral Lung

Contralateral Breast

Ipsilateral Breast

PTV

Structure

Author Manuscript
0 (0.0%)
55 (100.0%)
0 (0.0%)
0 (0.0%)
52 (96.3%)
1 (1.9%)
1 (1.9%)

>20% of the lung received 30% of the prescribed dose
< 15% of the lung received 5% of the prescribed dose.
15–20% of the lung received 5% of the prescribed dose.
>20% of the lung received 5% of the prescribed dose.
Right-sided lesions: < 5% of the heart received 5% of the prescribed dose.
Left-sided lesions: <40% of the prescribed dose to the V5
Right-sided lesions: 5–10% of the heart should receive 5% of the prescribed dose
Left-sided lesions: 40–45% of the prescribed dose to the V5
Right-sided lesions: >10% of the heart received 5% of the prescribed dose
Left-sided lesions: >45% of the prescribed dose to the V5
Maximum point dose of 3% of the prescribed dose.

Deviation Unacceptable
Per Protocol
Variation Acceptable
Deviation Unacceptable
Per Protocol
Variation Acceptable
Deviation Unacceptable
Per Protocol

0 (0.0%)
0 (0.0%)

>3–5% of the prescribed dose
>5% of the prescribed dose

Variation Acceptable
Deviation Unacceptable

54 (100.0%)

5 (9.1%)

Per Protocol

50 (90.9%)

>5% of the prescribed dose to the contralateral breast

Deviation Unacceptable

15–20% of the lung received 30% of the prescribed dose

1 (1.8%)

3–5% of the prescribed dose to the contralateral breast

Variation Acceptable

< 15% of the lung received 30% of the prescribed dose

2 (3.6%)

< 3% of the prescribed dose to the contralateral breast

Per Protocol

Variation Acceptable

3 (5.5%)
52 (94.5%)

>65% of the whole breast reference volume should receive ≥50% of the prescribed dose

Deviation Unacceptable

45 (81.8%)

<60% of the whole breast reference volume should receive ≥50% of the prescribed dose and <35 % of the whole breast reference
volume should receive the prescribed dose. The whole breast reference volume is defined as per Supplemental Appendix.

Per Protocol

7 (12.7%)

0 (0.0%)

If the PTV-EVAL dosimetric coverage goals exceed 5% of the guidelines. Maximum dose exceeds 120% of the prescription
dose.

Deviation Unacceptable

60–65% of the whole breast reference volume should receive ≥50% of the prescribed dose

1 (1.8%)

All specified PTV-EVAL dosimetric coverage goals fall within 5% of the guidelines. Maximum dose is 110%–120% of the
prescription dose.

Variation Acceptable

Variation Acceptable

54 (98.2%)

>90% of the prescription isodose surface covers >90% of the PTV_EVAL. Maximum dose does not exceed 110% of the
prescription dose.

Per Protocol

n (%)

Criteria

Score

Dose Constraints for Critical Structures and Scoring

Author Manuscript

Table 5
Arthur et al.
Page 16

Author Manuscript
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Author Manuscript
0
0

2
0

1
1
9
1

Generalized muscle weakness

Joint range of motion decreased

Superficial soft tissue fibrosis

NERVOUS SYSTEM DISORDERS

Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.
3
0
0
0

3
3

Erythema multiforme

Pruritus

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

1

0

1

Reproductive system and breast disorders - Other
32

0

14

Breast pain

Dry skin

6

6

3

13

0

0

2

0

Breast atrophy

REPRODUCTIVE SYSTEM AND BREAST DISORDERS

1

10

Fibrosis deep connective tissue

Paresthesia

1

1

0

0

0

Chest wall pain

1

3

Back pain

DISORDERS

19

2

Seroma

MUSCULOSKELETAL AND CONNECTIVE TISSUE

1

14

Dermatitis radiation
1

2

16

INJURY, POISONING AND PROCEDURAL COMPLICATIONS

Soft tissue infection

1

0

1

4

Skin infection

2

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

0

1

2

0

2

1

0

0

1

1

3

Grade
2

Breast infection

35

INFECTIONS AND INFESTATIONS

1

Worst Skin, Fibrosis, and Breast Pain

System Organ Class Term

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

4

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

5

Number of Patients with an Adverse Event by System Organ Class and Grade Definitely, Probably, or Possibly Related to Protocol Treatment Occurring ≤
1 Year from the Completion of Reirradiation in the First 55 Evaluable Patients
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1
0

2

Skin induration

3

Lymphedema
Skin, Fibrosis, and Breast Pain Adverse Events

1

Hot flashes

VASCULAR DISORDERS

0

0

0

0

1
10

Skin hypopigmentation

4

2

Telangiectasia

0

2
25

Skin hyperpigmentation

0

6

Skin and subcutaneous tissue disorders - Other
Skin atrophy

2

Author Manuscript
1

Author Manuscript

System Organ Class Term

1

0

1

0

0

0

0

0

0

3

Grade

0

0

0

0

0

0

0

0

0

4

0

0

0

0

0

0

0

0

0

5

Arthur et al.
Page 18

Author Manuscript

Author Manuscript

Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.

